Co-Diagnostics, Inc.
CODX Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 23, 2026
$0.55
KIRA · Stoqly’s AI analyst, in plain words
- Co-Diagnostics, Inc. had $0.6M of revenue in fiscal 2025, down 84.1% on the year before. Over five years, revenue changed −61.6% a year on average.
- Its operating margin was −8,058.7%, down 7,035.0 pts: of every 100 in sales, about −8,059 is left after running the business.
- Co-Diagnostics, Inc. lost $46.9M in fiscal 2025.
- Free cash flow was −$29.8M in fiscal 2025, −4,793.1% of revenue.
Market cap
$2.4M
P/E
—
Revenue
$0.6M
Net income
−$46.9M
Free cash flow
−$29.8M
Operating margin
−8,058.7%
Co-Diagnostics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−84.1%
No. Sales fell 84.1% last year.
Does it make a profit?
−7,533.5%
No. It lost money last year.
Does profit turn into cash?
−4,793.1%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 8
Weak. It passes 1 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Co-Diagnostics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Legal name
- Co-Diagnostics, Inc.
- CIK
- 0001692415
Co-Diagnostics, Inc. · CODX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $97.9M | $34.2M | $6.8M | $3.9M | $0.6M |
| Revenue growth | 31.3% | −65.0% | −80.1% | −42.5% | −84.1% |
| Gross margin | 88.2% | 84.0% | 38.6% | 74.5% | 64.3% |
| Operating margin | 47.1% | −78.8% | −626.9% | −1,023.7% | −8,058.7% |
| Net income | $36.7M | −$14.2M | −$35.3M | −$37.6M | −$46.9M |
| Net margin | 37.5% | −41.6% | −518.7% | −961.4% | −7,533.5% |
| Diluted EPS | $1.23 | −$0.45 | −$1.20 | −$37.22 | −$35.25 |
| Cash | |||||
| Cash from operations | $41.1M | $6.6M | −$22.1M | −$29.2M | −$29.1M |
| Capital expenditure | $0.7M | $1.4M | $1.4M | $0.7M | $0.7M |
| Free cash flow | $40.4M | $5.1M | −$23.4M | −$29.9M | −$29.8M |
| FCF margin | 41.3% | 15.0% | −344.2% | −763.8% | −4,793.1% |
| Share buybacks | — | $14.2M | $1.4M | — | — |
| Share count change | 6.8% | 5.3% | −6.8% | −96.6% | 31.5% |
| Debt and strength | |||||
| Cash and short-term investments | $89.9M | $81.3M | $58.5M | $29.7M | $11.9M |
| Shareholders' equity | $134M | $115M | $85.6M | $53.9M | $20.6M |
| Current ratio | 9.1x | 23.9x | 10.8x | 4.4x | 3.9x |
| Returns and quality | |||||
| Return on equity | 36.4% | −11.4% | −35.3% | −54.0% | −125.9% |
| Return on tangible equity | 39.6% | −16.2% | −59.7% | −135.5% | −349.7% |
| Piotroski F-score | 4 | 3 | 2 | 3 | 1 |
| Altman Z'' | 12.8 | 18.4 | 10.7 | 2.5 | −16.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Co-Diagnostics, Inc. · CODX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.55 a share, the company is worth $2.4M.
Source: SEC EDGAR XBRL filings (CIK 0001692415). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.